Recorded device evidence

EZ GLIDE AORTIC CANNULA, AORTIC PERFUSION CANNULA WITH DURAFLO COATING, DISPERSION AORTIC PERFUSION CANNULA (K123370): indications, design and recorded evidence

The acquired K123370 file contains product-specific indications and users, design and operating principle, non-clinical evidence actually described sections. Compare these dated manufacturer statements with your own indication and design before commissioning evidence work. They describe this submission; they do not prescribe your testing, validate performance independently or establish a suitable predicate.

Evidence retrieved 2026-10-08. Source versions and topic-specific limits are listed below.

Computed exact-code research

This decision beside its recorded product-code cohort

The 2021–2025 complete-year cohort contains 16 selected decisions under primary code DWF. 16 have valid reported receipt/decision pairs; 0 pairs are missing or invalid.

No quartiles are displayed: this complete-year cohort has fewer than 20 valid pairs.

The table shows the named decision and up to four latest exact-code research records through 2026-09-27. It can include partial-year records outside the complete-year cohort. The quartiles above use the full stated cohort, not this displayed selection.

Research recordRecorded deviceReceipt → decisionCalendar elapsed daysRecorded submission type
K123370 ↗ · this pageEZ GLIDE AORTIC CANNULA, AORTIC PERFUSION CANNULA WITH DURAFLO COATING, DISPERSION AORTIC PERFUSION CANNULA2012-11-01 → 2013-03-13132Traditional
K260195 ↗Elongated One-Piece Arterial (EOPA) 3D™ Arterial Cannulae2026-01-22 → 2026-04-2391Special
K250937 ↗Venous Return Cannulae2025-03-28 → 2026-03-11348Traditional
K260043 ↗Smart Reactors Camouflage Coated Extracorporeal Cardiopulmonary Tubing Set (SR180C)2026-01-07 → 2026-02-2347Traditional
K253203 ↗Retrograde Coronary Sinus Perfusion Cannulae2025-09-26 → 2026-02-19146Traditional

Use this comparison: select a record to investigate, read its actual indications and design, and document differences. A shared code or elapsed period cannot establish its relevance to your device.

Calendar elapsed days are not active FDA review time, a promised schedule or a success probability. The selection includes only the stated recorded decisions, not all applications. Latest records can postdate the named historical decision and are contextual research, not its predicates. Shared codes, summaries and observed records do not prove equivalence, current market availability, buyer applicability or predicate suitability.

Calculation, selection and source versions

Reuse the complete-endpoint exact-primary-code, documented SE-decision cohort and its stated cutoff/window. Retain its type-7 quartiles only when at least 20 valid date pairs are present. Independently subtract the named official record’s receipt date from its decision date; missing or negative pairs remain unknown. Show up to four latest exact-code research records, excluding the named ID. Parent analysis hash, source snapshots and calculation versions are retained.

Calculation: fda-named-decision-cohort-context-1; cutoff 2026-09-27; 0 parent records excluded; units record counts; calendar elapsed days.

Source snapshots: 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002.

Read beyond the decision row

Recorded evidence and differences to investigate

The summary is manufacturer-submitted context hosted by FDA. Negative/no-study statements are preserved. Evidence themes are not binding legal requirements.

Short opening excerpts identify the source sections. Read the linked original for the full study context, negative statements, tables and limitations. Public quotations are limited to 120 words per acquired summary; the internal evidence packet retains exact section ranges for review.

Indications and users

K123370 · PDF page 2 ↗ Source 2

Aortic          perfusion      cannulse    are         Intended       for       perfusion         of the      aorta        during       short-term
(5  6 hours)         cardiopulmonary       bypass         procedures.

Aortic          Perfusion      Cannulae          may       be        used     in pediatric       or     adult       populations       based       on        the
flow    rate         requirements         and           individual     patient        anatomy.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

Design and operating principle

K123370 · PDF page 1 ↗ Source 3

Edwards     Aortic         Perfusion          Cannulae        are      sterile,       non-pyrogenic,          single-use       cannulae
made          of flexible     and       non-flexible        polymeric      materials.        They    are       intended        for       perfusion     of
the     ascending     aorta        during       cardiopulmonary        bypass     procedures.

The excerpt is shortened at a complete statement. Read the complete section in the original PDF before interpreting the evidence.

Compare with your product: Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

Non-clinical evidence actually described

K123370 · PDF page 2 ↗ Source 2

Bench          and       laboratory      testing      was      performed            and     assures        that  the     product      meets           its
specifications      per      the  table       below.                            The       performance         testing      met      the      acceptance          criteria.

Compare with your product: Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

Extraction selection and limits

Select observed whole-line section headings or explicit colon-delimited inline labels on readable PDF pages, including the explicitly documented heading-spacing variants in this parser version. Preserve the original heading, character ranges and layout; do not repair excerpt text. Exclude letter boilerplate and uncertain pages. Stop at observed table headings; do not infer table columns or scalar results from layout text. Multi-column or suspicious split-numeric excerpts are excluded until reviewed alternate extraction is available. Original layout records remain retained; any alternate text has its own extractor-version locator and requires original-page review. For each dimension, prefer usable versioned alternate text where available, selecting its longest usable excerpt; otherwise select the longest usable original-layout excerpt. Ties preserve source order. Bounded to 64 PDF pages and 3,500 characters per section. This is a selection, not a complete dossier analysis.

Excluded extraction items: {}.

Known facts and deciding inputs

Known context: US. Confirm the organisation’s role, relevant activities and markets against the cited criteria.

Source factRecorded valueWhat to check
510(k) identifierK123370 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Generic device categoryEZ GLIDE AORTIC CANNULA, AORTIC PERFUSION CANNULA WITH DURAFLO COATING, DISPERSION AORTIC PERFUSION CANNULA [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded applicantEdwards Lifesciences, LLC [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
FDA product codeDWF [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Decision date2013-03-13 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Recorded decision codeSESE [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Submission typeTraditional [1]Dated official record fact; not proof of current commercial availability or applicability to another device.
Receipt date2012-11-01 [1]Dated official record fact; not proof of current commercial availability or applicability to another device.

Prepare a differences and evidence worksheet

Use this checklist to gather your business or product details before speaking with a specialist. The items below explain what to record and suggest useful supporting documents. You can add your own answers in the editable project brief.

  1. Indications and users — what differs in our product?

    Compare the recorded indication, population, body site and use environment with your proposed label. Record each change instead of assuming the primary code settles intended use.

    Useful evidence: Our proposed indication, user/population and use environment beside this exact recorded indication.

  2. Design and operating principle — what differs in our product?

    Compare physical design, materials, energy, accessories and operating principle with your design. Ask which documented differences change the evidence scope.

    Useful evidence: Design description, materials/components, accessory list and a differences matrix.

  3. Non-clinical evidence actually described — what differs in our product?

    Treat these as documented evidence themes in this case, including any limitations or negative statements. Ask which protocols, design inputs and acceptance rationale would be justified for your product; these excerpts are not a mandatory test panel.

    Useful evidence: Existing protocols/results and design-specific evidence gaps, with standard editions and scope reviewed separately.

Work packages and dependencies

Questions for providers

Sources and data dates

Read the official document in context. The audit details identify the precise locators and preserved versions used for this page.

FDA openFDA — 510(k) decision records ↗

2026-10-05 · retrieved 2026-10-06

Audit details: precise locators and snapshot identifiers

Source key D01 · snapshot 5a86994ba49a37e71e09be96803fd51981c6c43eaa96caab41aea2b188bfe002

  • [1] device-510k-0001-of-0001.json:results[17323] · record fc7d67442e3fe49bcdd6d0357361e5852ef5507d9be6131bcfa865e8e134d30c
  • [4] Complete results array / fda-decision-context:K123370 · record whole dataset partition

FDA 510(k) summary — K123370 ↗

Thu, 11 Apr 2013 16:52:58 GMT · retrieved 2026-10-08

Audit details: precise locators and snapshot identifiers

Source key D02 · snapshot adc9027c0ba6e536c77619c42a9543b5f5bfad464ce35450a4da63d199cc7444

  • [2] PDF page 2 · record 3d0facc0eaf4f25f32cce0fc44f35924d1bafdf2cfefd4161ef15cdf0c2d262b
  • [3] PDF page 1 · record 61ca6a324aaacc2ba5bb09d9aff01438904a54e79fce2fb368c06065e0c3894f

Prepare an editable project brief

Confirm the facts, scope and contact preference before sharing your project. Preparing this page sends no provider outreach.

Choose work packages to discuss

Compare FDA 510(k) Submission Services